Moreover, an important caveat of the BRAF inhibitors monotherapies is the paradoxical activation of the MAPK pathway, according to which, a RASmut background contraindicates the administration of BRAF inhibitors due to tumor potentiation [38,39]. The gene discussed is BRAF; the disease is neoplasm.